EDTA, DMSA, modified citrus pectin and other chelation agents to promote the excretion of toxic minerals and maintain healthy arteries.
Lead, mercury and other toxic trace minerals accumulate continuously in the body over time (New Eng. J. Med, 1899, 321:979). Plaque deposits that clog up the circulation system are built up mainly around mineral deposits of calcium and toxic minerals in the vascular system. These deposits gradually harden into a cement-like structure that block arteries, thereby causing heart attacks, stroke and other vascular diseases. Chelating agents bind these minerals as chelates, enabling them to be safely excreted in the urine and faeces.
EDTA is widely used as a chelating agent, and EDTA therapy is approved in the US as a treatment for lead and heavy metal poisoning. Although it does not bind mercury strongly, it has a great affinity for aluminium.
DMSA is also approved by the FDA in the US to remove lead from the brains of children who are lead-poisoned, and is included specifically because it binds mercury better than other chelating agents.
Pectin is combined with an alkalanizing agent (potassium carbonate) to convert the carboxyl groups in pectin to the salt form to enhance it’s mineral binding capacity. Trials and studies revealed that orally administered modified citrus pectin supplements significantly increase urinary excretion of toxic metals present in the body.
L-Arginine generates nitric oxide that relaxes vascular walls, while vitamin K suppresses calcification of the arteries. Betaine and folic acid prevent the accumulation of toxic homocysteine. Niacin dilates arteries, thus improving tissue percolation.
To lower high blood and tissue levels of toxic minerals and thereby contribute towards preventing atherosclerosis and Alzheimers disease. (Neurobiology of Aging, 2002, 23:1031). The American College for Advancement of Medicine strongly supports the use of EDTA for cardiovascular conditions.
Pregnancy, lactation, patients with demonstrated essential mineral deficiencies, patients with active tuberculosis.
Use with caution in patients with pre-existing heart rythm irregularities. EDTA may adversely affect blood sugar control. Use with care in patients with compromised liver and renal function. Do not use the product without supplementing with essential minerals.
EDTA may decrease serum potassium levels. This may be of concern in patients on potassium depleting diuretics.
PREGNANCY AND LACTATION
Do not use during pregnancy or lactation.
DOSAGE AND DIRECTIONS OF USE
Take two capsules three times daily with meals for an initial period of three months. Then reduce to one capsule three times daily.
SIDE EFFECTS AND SPECIAL PRECAUTIONS
None at normal dosage levels.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Securitainer containg 120 capsules.